Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00139230 · ClinicalTrials.gov registry record · Phase 2
Combination Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck
A Phase 2 study of Squamous Cell Carcinoma and Carcinoma of Head/Neck, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 2
- Study locations
NCT00139230: Completed Phase 2 study of Squamous Cell Carcinoma and Carcinoma of Head/Neck, sponsored by Dana-Farber Cancer Institute.
NCT00139230 is a Phase 2 study of Squamous Cell Carcinoma and Carcinoma of Head/Neck that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 30 participants, below the 103-participant average among 47 other Squamous Cell Carcinoma trials with a reported enrollment target (71% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00139230, a Phase 2 study of Squamous Cell Carcinoma and Carcinoma of Head/Neck, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to further test a combination chemotherapy regimen for the treatment of squamous cell carcinoma of the head and neck and to see if the addition of supportive medicine can help reduce the side effects of these drugs.
Conditions Studied
Interventions
- DRUG Cisplatin
- DRUG Leucovorin
- DRUG G-CSF
- DRUG 5-Fluorouracil
- DRUG Taxotere
Study Locations (2)
Massachusetts
- Massachusetts General Hospital - Boston
- Dana-Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 1997-01 |
| Est. Completion | 2006-12 |
| Phase | Phase 2 |
What the finished NCT00139230 record still lists
NCT00139230 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 103-participant average among 47 other Squamous Cell Carcinoma trials with a reported enrollment target (71% lower).
The record links to 2 conditions, with Squamous Cell Carcinoma appearing as the primary indexed condition, and to 5 interventions - of which Cisplatin is the first listed.
NCT00139230 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00139230 about?
NCT00139230 is a clinical study titled "Combination Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck". The purpose of this study is to further test a combination chemotherapy regimen for the treatment of squamous cell carcinoma of the head and neck and to see if the addition of supportive medicine can help reduce the side effects of these drugs.
What is the current status of trial NCT00139230?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 1997-01. Estimated completion is 2006-12.
What conditions does trial NCT00139230 study?
This clinical trial studies the following conditions: Squamous Cell Carcinoma, Carcinoma of Head/Neck.
What interventions are being tested in trial NCT00139230?
The interventions under investigation include: Cisplatin (DRUG), Leucovorin (DRUG), G-CSF (DRUG), 5-Fluorouracil (DRUG), Taxotere (DRUG).
Who is sponsoring clinical trial NCT00139230?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00139230 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Squamous Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00139230's enrollment target sits among peer trials
30 31st of 47 higher than 14 of 47 other Squamous Cell Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Squamous Cell Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Afatinib in Advanced Cutaneous Squamous Cell Carcinoma
RECRUITING · Phase 2
-
Impact of COL7A1 Gene Therapy on SCC Recurrence in RDEB Skin
RECRUITING · Phase 2
-
Toripalimab With Chemotherapy for Sinus Cancer
RECRUITING · Phase 2
-
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
RECRUITING · Phase 2
-
Preoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck
RECRUITING · Phase 2
-
Immunotherapy With Chemotherapy and Chemoradiation for Advanced Squamous Cancer of Nasal Cavity / Paranasal Sinuses (I-NAPA)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia